^(99m)Tc-DTPA-DG显像对非小细胞肺癌化疗疗效的评价

Assessment of chemotherapeutic efficacy on non-small cell lung cancer by ^(99m)Tc-DTPA-DG imaging

目的:探讨99m Tc-DTPA-脱氧葡萄糖(DG)对非小细胞肺癌荷瘤裸鼠化疗疗效的评价。方法:建模成功后的A549肺癌裸鼠分为2组:A组为对照组(NS);B组为顺铂组(DDP)。裸鼠化疗疗程完成后分别于次日和第7、14、21、28 d注射99mTcDTPA-DG 3.7 MBq/只,0.5 h后显像,勾画感兴趣区(ROI),计算肿瘤/健侧对应部位放射性(T/TN)比值,并测量肿瘤体积。第28 d完成显像后处死裸鼠,测量肿瘤/血液及肿瘤/肌肉放射性比值,计算抑瘤率,并剥离瘤组织,测量质量。结果:肿瘤组织吸收99mTc-DTPA-DG较多,肿瘤/血液放射性比值对照组为3.95,高于顺铂组(0.89,t=3.282,P<0.05)。肿瘤/肌肉放射性比值对照组为6.73,高于顺铂组(0.81,t=4.096,P<0.05)。99mTc-DTPA-DG可使肿瘤组织清晰显像,第28 d顺铂组与对照组肿瘤体积分别为388.64mm3、1052.41mm3,差异有统计学意义(t=4.053,P<0.05)。结论 :顺铂对非小细胞肺癌化疗后,99mTc-DTPADG显像示肿瘤体积缩小,瘤体内放射性分布降低,99m Tc-DTPA-DG显像可用于非小细胞肺癌化疗疗效的评估。

Objective To investigate the feasibility of using 99mTc -DTPA -DG imaging to assess chemotherapeutic efficacy on non-small cell lung cancer（NSLC）. Methods：Twenty male nude rats inoculated with A549 cell were randomly divided into two groups. The control group was treated with 2 mL/kg of saline. The DDP group was treated with 2 mL/kg of Cisplatin. Scintigraphic studies were conducted 1, 7, 14, 21 and 28 d after the treatment. The radioactivity ratios of tumor to non-tumor （T/NT） was calculated with the region of interest （ROI） technique. After the last imaging the rats were sacrificed. The radioactivity ratios of tumor/ blood and tumor/muscle were measured. Tumor volume and thereby the inhibition rate in both groups were calculated. ResultsThe tumor cells took more 99mTc-DTPA-DG than normal tissues. The control group had higher tumor/ blood ratio （3.95） and tumor/muscle ratio （6.73） than DDP group （0.89, 0.81, t = 3.282, t =4.096,P〈0.05）. Tumors were clearly visualized on the 99mTc-DTPA-DG images. The tumor volume of DDP group and contyol group at the 28th day was 388.64 mm3 and, 1052.41 mm3 respectively, which is statistical significant （t = 4.717 , P 〈 0.05）. ConclusionThe decrease of tumor volume and radioactivity ratio after the chemotherapy of DDP can be distinctively demonstrated which prores that the 99mTc-DTPA-DG images could be used to evaluate the chemo-therapeutic efficacy on non-small cell lung cancer.